title: Improving the prognosis ways of central genesis and management option in infertile women.
abstract: To study central genesis of disfunctional menstrual disorders was based particulary on electroencephalography and find out efficacy of pathogenetic management in infertile women with central forms of oligomenorrhoea and amenorrhoea compared to generally accepted hormone therapy.   Depending on received management, all 159 patients were divided into two groups. Group I included 93 women with infertility and menstrual disorders treated by taking into account the found cerebral dysfunction. Group II included 66 women received generally accepted hormone therapy.  26 women belonged to group I were found to have regulated menstrual cyclicity (28%) after neuro-mediatorical management with tegretol, finlepsin, cinnarizin, phenazepam,- received during 3-6 months. In group II, in 3 women (4.5%) was obtained improvement and period became regular by using hormone treatment, included Diane-35, Tri-Regol, Marvelon subsequently by generally accepted way during long lasting courses (12 months- more than 1 year). Pregnancy occurred in 17 cases in group I (18.3%). The difference was significantly higher in this group in comparison with group II, where pregnancy was attained only in 3 women (4.5%).  Our findings indicate that in the basis of menstrual disorders observed in 159 infertile women were stood dysfunctional changes of central regular mechanisms. Pathogenetic therapy showed that we have taken into consideration neuro-mediatorical correction of found central nervous system level dysfunction. By this way our study reveals significant success of management with neuro-mediatorical purpose compared to the generally accepted hormone therapy.
authors.affiliation: Research Institute of Obstetrics and Gynecology, Minisrty of Health, Baku, Azerbaijan.
authors.forename: N
authors.initials: N
authors.lastname: Halilova
mesh_terms: D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000150:complications* / Q000188:drug therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000150:complications*; D002936:Cinnarizine / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use; D017135:Desogestrel / Q000627:therapeutic use; D004338:Drug Combinations; D004569:Electroencephalography; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology*; D009839:Oligomenorrhea / Q000150:complications* / Q000188:drug therapy*; D011372:Progestins / Q000627:therapeutic use; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000726:Androgen Antagonists; D004338:Drug Combinations; D011372:Progestins; D002220:Carbamazepine; D002936:Cinnarizine; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D017135:Desogestrel